
浏览全部资源
扫码关注微信
1.鄂州市中心医院手术麻醉科,湖北 鄂州436000
2.鄂州市中心医院耳鼻喉科,湖北 鄂州436000
杨志军,E-mail:dingyih21427@163.com
纸质出版日期:2024-11-25,
收稿日期:2023-11-10,
移动端阅览
熊浪,魏媛媛,杨志军.布托啡诺复合帕瑞昔布钠在悬雍垂腭咽成形术后自控镇痛中的效果分析[J].局解手术学杂志,2024,33(11):941-944.
XIONG Lang,WEI Yuan-yuan,YANG Zhi-jun.Analysis of the effect of butorphanol combined with parecoxib sodium on patient-controlled intravenous analgesia after uvulo-palato-pharyngo-plasty[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):941-944.
熊浪,魏媛媛,杨志军.布托啡诺复合帕瑞昔布钠在悬雍垂腭咽成形术后自控镇痛中的效果分析[J].局解手术学杂志,2024,33(11):941-944. DOI: 10.11659/jjssx.11E023047.
XIONG Lang,WEI Yuan-yuan,YANG Zhi-jun.Analysis of the effect of butorphanol combined with parecoxib sodium on patient-controlled intravenous analgesia after uvulo-palato-pharyngo-plasty[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):941-944. DOI: 10.11659/jjssx.11E023047.
目的
2
探究布托啡诺复合帕瑞昔布钠用于悬雍垂腭咽成形术(UPPP)后患者静脉自控镇痛(PCIA)中的效果。
方法
2
选取2021年10月至2023年5月我院收治的拟行UPPP的患者80例,按照随机数字表法分为帕瑞昔布钠组(D组)、布托啡诺小剂量组(B1组)、布托啡诺中剂量组(B2组)、布托啡诺大剂量组(B3组),每组20例。D组患者使用40 mg帕瑞昔布钠+0.9%氯化钠注射液镇痛;B1组、B2组、B3组患者在D组基础上分别复合3.0 μg·kg
-1
·h
-1
、4.0 μg·kg
-1
·h
-1
、5.0 μg·kg
-1
·h
-1
布托啡诺进行PCIA。比较各组患者PCIA前及PCIA后2 h、12 h、24 h、48 h的心率和平均动脉压;比较各组患者在PCIA后2 h、12 h、24 h、48 h的疼痛视觉模拟评分法(VAS)评分、Ramsay评分;记录PCIA按压次数及术后不良反应发生情况。
结果
2
PCIA前及PCIA后2 h、12 h、24 h、48 h,各组患者的心率和平均动脉压比较,差异均无统计学意义(
P
>
0.05)。与D组相比,PCIA后2 h、12 h、24 h、48 h,B1、B2、B3组患者的VAS评分显著降低(
P
<
0.05),且布托啡诺剂量越高,VAS评分越低(
P
<
0.05)。与D组相比,PCIA后2 h、12 h、24 h、48 h,B1、B2、B3组患者的Ramsay评分显著升高(
P
<
0.05),且布托啡诺剂量越高,Ramsay评分越高(
P
<
0.05)。B3组患者不良反应总发生率显著高于D组、B1组、B2组(
P
<
0.05);与D组相比,B1组、B2组、B3组患者的PCIA按压次数显著减少(
P
<
0.05),且布托啡诺剂量越高,PCIA按压次数越少(
P
<
0.05)。
结论
2
布托啡诺复合帕瑞昔布钠用于UPPP后PCIA的效果较好,且复合4.0 μg·kg
-1
·h
-1
的帕瑞昔布钠镇痛效果更显著,安全性更高。
Objective
2
To investigate the effect of butorphanol combined with parecoxib sodium on patient-controlled intravenous analgesia (PCIA) after uvulo-palato-pharyngo-plasty (UPPP).
Methods
2
Eighty patients who were admitted to our hospital from October 2021 to May 2023 and planned to receive UPPP were collected, and they were randomly assigned to the paroxicib sodium group (D group), the butorphanol low-dose group (B1 group), the butorphanol medium dose group (B2 group), and the butorphanol high-dose group (B3 group), with 20 cases in each group. Patients in the D group received 40 mg of paroxycoxib sodium with 0.9% sodium chloride injection for analgesia, and patients in the B1 group, the B2 group, and the B3 group were combined with 3.0 μg·kg
-1
·h
-1
, 4.0 μg·kg
-1
·h
-1
,and 5.0 μg·kg
-1
·h
-1
of butorphanol respectively on the basis of D group. The heart rate and mean arterial pressure before PCIA and 2 hours, 12 hours, 24 hours, and 48 hours after PCIA were compared among the four groups; the pain visual analogue scale (VAS) score, Ramsay score 2 hours, 12 hours, 24 hours, and 48 hours after PCIA were compared among the four groups; the number of PCIA compression, and incidence of adverse reactions were recorded.
Results
2
There was no statistically significant difference in the heart rate or mean arterial pressure before PCIA and 2 hours, 12 hours, 24 hours, and 48 hours after PCIA among the four groups (
P
>
0.05). Compared with the D group, the VAS scores 2 hours, 12 hours, 24 hours, and 48 hours after PCIA of the B1, B2, and B3 groups significantly decreased (
P
<
0.05), and the higher the dose of butorphanol, the lower the VAS score (
P
<
0.05). Compared with the D group, the Ramsay scores 2 hours, 12 hours, 24 hours, and 48 hours after PCIA of the B1, B2, and B3 groups obviously increased(
P
<
0.05), and the higher the dose of butorphanol, the higher the Ramsay score (
P
<
0.05). The total incidence of adverse reactions in the B3 group was obviously higher than that in the D group, the B1 group, and the
B2 group (
P
<
0.05). Compared with the D group, patients in the B1, B2, and B3 groups had significantly fewer PCIA compressions (
P
<
0.05), and the higher the dose of butorphanol, the fewer the PCIA compressions (
P
<
0.05).
Conclusion
2
The effect of butorphanol combined with parecoxib sodium in PCIA after UPPP is better, and combined with 4.0 μg·kg
-1
·h
-1
parecoxib sodium has more significant analgesic effect and higher safety.
布托啡诺帕瑞昔布钠悬雍垂腭咽成形术患者静脉自控镇痛效果
butorphanolparoxicib sodiumuvulo-palato-pharyngo-plastypatient-controlled intravenous analgesiaeffect
付桂玲,刘颖. 止鼾安神汤联合持续气道正压通气治疗阻塞性睡眠呼吸暂停低通气综合征伴失眠患者的临床疗效分析[J]. 世界睡眠医学杂志, 2021, 8(5):788-791.doi:10.3969/j.issn.2095-7130.2021.05.019http://dx.doi.org/10.3969/j.issn.2095-7130.2021.05.019.
刘奕罕, 朱宁, 薛孟周, 等. 阻塞性睡眠呼吸暂停低通气综合征伴脑卒中患者睡眠状况对情绪及日间疲劳的影响[J]. 实用临床医药杂志, 2023, 27(17):77-81.doi:10.7619/jcmp.20231598http://dx.doi.org/10.7619/jcmp.20231598.
丹静静, 陶树东, 阎朝晖. 悬雍垂腭咽成形术对OSAHS患者咽喉反流的影响[J]. 听力学及言语疾病杂志, 2020, 28(1):53-56.doi:10.3969/j.issn.1006-7299.2020.01.014http://dx.doi.org/10.3969/j.issn.1006-7299.2020.01.014.
李红艳,陈金,王娅,等.丁丙诺啡透皮贴联合PCIA在全膝关节置换术后镇痛中的应用疗效[J].局解手术学杂志,2021,30(5):442-445.doi:10.11659/jjssx.10E020084http://dx.doi.org/10.11659/jjssx.10E020084.
王谋江, 程翩翩, 王鹏, 等. 帕瑞昔布钠与氟比洛芬酯用于骨折术后镇痛效果的评估[J]. 安徽医药, 2021, 25(9):1874-1877.doi:10.3969/j.issn.1009-4393.2012.15.100http://dx.doi.org/10.3969/j.issn.1009-4393.2012.15.100.
Kumari A, Chhabra H, Gupta R,et al. Comparative study of effectiveness of tramadol and butorphanol as adjuvants to levobupivacaine for supraclavicular brachial plexus block[J]. Anesth Essays Res, 2019, 13(3):446-451.doi: 10.4103/aer.AER_110_19http://dx.doi.org/10.4103/aer.AER_110_19.
Sankar A, Johnson SR, Beattie WS, et al. Reliability of the American Society of Anesthesiologists physical status scale in clinical practice[J].Br J Anaesth,2014,113(3):424-432.doi:10.1093/bja/aeu100http://dx.doi.org/10.1093/bja/aeu100.
刘芳卉,胡乐农,徐红伟.低温等离子消融技术与电刀凝切技术在OSAHS中的应用效果对比[J].中国中西医结合耳鼻咽喉科杂志, 2024,32(1):46-50.doi:10.16542/j.cnki.issn.1007-4856.2024.01.010http://dx.doi.org/10.16542/j.cnki.issn.1007-4856.2024.01.010.
李潇湘,丁慧娟,罗秋平,等.超声下喉上神经阻滞复合右美托咪定对UPPP术后留置气管导管的患者镇静镇痛的作用[J].医学临床研究,2020,37(3):432-434.doi:10.3969/j.issn.1671-7171.2020.03.033http://dx.doi.org/10.3969/j.issn.1671-7171.2020.03.033.
银兴贵. 悬雍垂腭咽成形术联合同期鼻腔扩容术治疗阻塞性睡眠呼吸暂停低通气综合征的临床观察[J].中国药物与临床, 2021, 21(7):1122-1124.doi:10.11655/zgywylc2021.07.027http://dx.doi.org/10.11655/zgywylc2021.07.027.
赵鹏, 凌月福. 自控静脉镇痛法对改良悬雍垂腭咽成形术术后患者IL-2、IL-6的影响[J].华夏医学,2016,29(2):1-4.doi:10.19296/j.cnki.1008-2409.2016-02-001http://dx.doi.org/10.19296/j.cnki.1008-2409.2016-02-001.
Chen PY, Samy W, Aaron Ying CL. Comparing cost and effectiveness of IVPCA morphine with perioperative multimodal analgesia of oral etoricoxib and oxycontin: a retrospective study[J]. J Orthop, 2019, 16(6):585-589.doi: 10.1016/j.jor.2019.06.012http://dx.doi.org/10.1016/j.jor.2019.06.012.
欧锋,井立说.咪达唑仑联合氟马西尼用于悬雍垂腭咽成形术麻醉苏醒期的有效性与安全性观察[J].检验医学与临床, 2022, 19(24):3437-3440.doi:10.3969/j.issn.1672-9455.2022.24.033http://dx.doi.org/10.3969/j.issn.1672-9455.2022.24.033.
赵竞余,姜丽杰,贾庆成,等.酒石酸布托啡诺对冠状动脉旁路移植术丙泊酚麻醉诱导期血流动力学的影响[J].局解手术学杂志,2023,32(4):346-350.doi: 10.11659/jjssx.08E022003http://dx.doi.org/10.11659/jjssx.08E022003.
杨林,孙德峰,吴越,等.布托啡诺经鼻给药超前镇痛对老年患者H-UPPP术后镇痛的影响[J].中国现代医学杂志, 2015, 25(9):59-63.doi:10.3969/j.issn.1005-8982.2015.09.012http://dx.doi.org/10.3969/j.issn.1005-8982.2015.09.012.
周珩,梁佐迪,刘炜炜,等.悬雍垂腭咽成形术后多模式镇痛临床研究[J].临床军医杂志, 2016, 44(11):1170-1171.doi:10.16680/j.1671-3826.2016.11.19http://dx.doi.org/10.16680/j.1671-3826.2016.11.19.
姚欣, 赵娴, 王甜. 右美托咪定联合布托非诺用于宫腔镜下异位妊娠手术术后镇痛效果及安全性分析[J].中国妇幼保健, 2021,36(2):374-378.doi:10.19829/j.zgfybj.issn.1001-4411.2021.02.042http://dx.doi.org/10.19829/j.zgfybj.issn.1001-4411.2021.02.042.
廖鑫,庾小翠,王韶, 等.右美托咪定复合布托啡诺在无痛支气管镜检查中的应用效果[J].中国内镜杂志, 2023, 29(7):1-7.doi:10.12235/E20220383http://dx.doi.org/10.12235/E20220383.
0
浏览量
1
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621